Home » EU/U.S. GMP Inspections Strategy Could Spell Relief for Drugmakers
EU/U.S. GMP Inspections Strategy Could Spell Relief for Drugmakers
January 10, 2012
The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) plan to step up cooperation on good manufacturing practice (GMP) inspections, moving from information-sharing and joint inspections to outright reliance on one another’s results.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor